O-13: Teplizumab (TPZ) in pediatric type 1 diabetes (T1D): Real-World screening, treatment, and disease management – TEPLI-REAL study
O-13: Teplizumab (TPZ) bei pädiatrischem Typ-1-Diabetes (T1D): Real-World-Screening, Behandlung und Krankheitsmanagement – TEPLI-REAL-Studie
Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)
DOI: 10.1159/hrp/adaag020.013 ↗Auf einen Blick
In einer retrospektiven Real-World-Studie mit 81 Minderjährigen war die TPZ-Behandlung meist vollständig. Während des Follow-ups begannen 26 % mit Insulin.
Fragestellung
Beschreibt die TEPLI-REAL-Studie Screening, Behandlungsabläufe und Krankheitsverlauf bei Kindern mit TPZ bei T1D?
Methode
Retrospektive Studie in den USA und Israel; eingeschlossen wurden Teilnehmer:innen <18 Jahre mit ≥1 Tag TPZ und Follow-up bis zur Datenerhebung.
Ergebnisse
81 Minderjährige; 54 % weiblich, 81 % weiß, medianes Alter bei TPZ-Start 12 y. 95 % schlossen den 14-tägigen Kurs ab, 91 % erhielten Standarddosierung. 26 % begannen Insulin.
Schlussfolgerung der Autor:innen
Die Studie zeigt hohe Abschlussraten der TPZ-Behandlung bei Kindern und liefert Einblicke in den Einsatz in der klinischen Praxis.
Kernaussagen
- 81 Minderjährige mit TPZ-Behandlung wurden analysiert
- 95 % schlossen den 14-tägigen TPZ-Kurs ab
- 26 % begannen während des Follow-ups Insulin
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von M Tuffaha und 13 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
TPZ is an anti-CD3 monoclonal antibody approved to delay stage 3 T1D in individuals aged ≥8 years (y) with stage 2 T1D.
Objectives
To characterize screening, treatment (Tx) patterns, and explore disease progression in children who received TPZ.
Methods
TEPLI-REAL (NCT06892002) was a retrospective study in the US and Israel. Eligible individuals received ≥1 day of TPZ and were followed until data abstraction; analysis included participants aged <18y.
Results
Of 81 minors (74% of enrolled individuals), 54% were female, 81% were white (race collected for US only, n=75), and median age at TPZ initiation was 12y (range 8–17). A family history of T1D in first-degree relatives was common (siblings 31%, fathers 12% and mothers 9%); 14 (17%) had ≥1 comorbidity at TPZ initiation, most commonly Hashimoto’s disease (n=4) and celiac disease (n=3). Islet autoantibody (IA) testing was most requested by a pediatric endocrinologist (n=38; 47%) and performed by Autoimmunity Screening for Kids/TrialNet (n=27; 33%). Positive IAs were found for GAD65 (98%), ZnT8 (86%), IA-2 (76%), and IAA (59%); the mean was 3.1 IA/individual. At screening, 73 (91%) had HbA1c tests (median 5.8%; range 4.8–11.5), 36 (45%) had oral glucose tolerance tests, and 7 (9%) had continuous glucose monitoring data. Dysglycemia was identified before IA positivity in 40%, after in 37%, and simultaneously in 23%. The median (range) time between stage 2 confirmation and TPZ initiation was 3.6 (0.6–119.6) mo. Time from TPZ initiation to stage 3 T1D in children identified by medical review as stage 2 (exploratory endpoint) was estimated. TPZ Tx occurred mainly in hospitals (48%) or infusion centers (38%); 95% completed the 14-day course and 91% followed standard dosing. During follow-up, 26% initiated insulin, of whom 10% for reasons other than rising blood glucose.
Conclusions
This study demonstrates high completion rates of TPZ Tx in children and provides insights into its use in clinical practice.
Zitieren
APA
Tuffaha, M., Felton, J., Graham, T., Simmons, K., Tirosh, A., Bonnemaire, M., Mukherjee, B., Manzano-Salgado, C. B., Dex, T., Kleinjung, F., Gwinnutt, J. M., Negreiro, F., Zaccai, J., & Gitelman, S. (2026). O-13: Teplizumab (TPZ) in pediatric type 1 diabetes (T1D): Real-World screening, treatment, and disease management – TEPLI-REAL study. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.013
Vancouver
Tuffaha M, Felton J, Graham T, Simmons K, Tirosh A, Bonnemaire M, et al. O-13: Teplizumab (TPZ) in pediatric type 1 diabetes (T1D): Real-World screening, treatment, and disease management – TEPLI-REAL study. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.013
BibTeX
@article{Tuffaha2026,
author = {Tuffaha, M and Felton, J and Graham, T and Simmons, K and Tirosh, A and Bonnemaire, M and Mukherjee, B and Manzano-Salgado, C B and Dex, T and Kleinjung, F and Gwinnutt, J M and Negreiro, F and Zaccai, J and Gitelman, S},
title = {O-13: Teplizumab (TPZ) in pediatric type 1 diabetes (T1D): Real-World screening, treatment, and disease management – TEPLI-REAL study},
journal = {Hormone Research in Paediatrics},
year = {2026},
volume = {99},
number = {Supplement_4},
doi = {10.1159/hrp/adaag020.013}
}
EUVIMED